Xilio Therapeutics (XLO) Debt to Equity (2020 - 2023)

Xilio Therapeutics has disclosed Debt to Equity across 4 years of filings, most recently posting $0.02 for Q1 2023.

• Debt to Equity for Q1 2023 came in at $0.02, down 62.15% year-over-year; the trailing twelve-month figure through Mar 2023 was $0.02 (down 62.15% YoY), and the FY2022 annual result was $0.03, down 42.3% from the prior year.
• Debt to Equity came in at $0.02 for Q1 2023 at Xilio Therapeutics, down from $0.03 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $0.05 in Q4 2021 to a low of -$0.09 in Q4 2020.
• The 4-year median for Debt to Equity is $0.03 (2022), against an average of $0.01.
• Across the five-year window, Debt to Equity surged 158.34% in 2021 and tumbled 62.15% in 2023, its largest moves.
• Xilio Therapeutics' Debt to Equity stood at -$0.09 in 2020, then soared by 158.34% to $0.05 in 2021, then plunged by 42.3% to $0.03 in 2022, then plunged by 39.06% to $0.02 in 2023.
• The last three Debt to Equity figures came in at $0.02 (Q1 2023), $0.03 (Q4 2022), and $0.04 (Q3 2022), per Business Quant data.